Bio Pharma Dive
JANUARY 19, 2022
Hal Barron, a key figure in GSK's efforts to revitalize its drug research, will step down as its top scientist at a time when the company is feeling heat from investors to deliver faster growth.
World of DTC Marketing
JANUARY 18, 2022
A Mediabistro survey showed that social networks influence more than 40% of people’s health choices. Tik-Tok, Instagram, and other social media channels may soon be overwhelmed with pharma companies’ content, but is it a good idea? People between 18 and 24 years of age tend to discuss health and wellness issues on social networks twice as much as those between the ages of 45 and 54 (getpushing.com), and of those between 18 and 24 years of age, 90% say they trust medical informatio
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Mirror
JANUARY 17, 2022
January 17, 2022 (Davis, CA) – Botanical Solution Inc. (BSI), innovator of sustainable, consistent, and cost-effective Advanced Botanical Materials for agricultural and pharmaceutical applications, has successfully closed $6.1 million in a Series A round led by Palo Alto based VC Firm, Otter Capital. This round of funding will enhance BSI’s value proposition by facilitating the geographic expansion of its current botanical-based products and the development of a new product pipeline derive
BioPharma Reporter
JANUARY 17, 2022
Vir Biotechnology and the Bill & Melinda Gates Foundation have partnered up to develop broadly neutralizing antibodies designed to provide a âvaccinal effectâ for the treatment of HIV and prevention of malaria.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bio Pharma Dive
JANUARY 21, 2022
After halting a Phase 3 trial of the drug last year, Roche went digging for more data. What it found led to plans for another trial, but the pharma's hypothesis may rest on shaky ground.
World of DTC Marketing
JANUARY 20, 2022
Many companies allocate an exponentially more significant percentage of their marketing budget to paid media over organic search. However, many brands are unaware of the waste inherently included in paid media. Organic search delivers results at a lower customer acquisition cost (CAC) than paid search — 87% lower cost, per research. According to Google, organic search also offers double the ROI that paid search does.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
JANUARY 21, 2022
Psyros Diagnostics has signed an agreement to be acquired by the Swedish company, Prolight Diagnostics AB. Psyros’s ground-breaking Point-of-Care (POC) technology enables the measurement of disease-indicating molecules in extremely low concentrations–in ten minutes or less.
Bio Pharma Dive
JANUARY 18, 2022
The FDA has extended by three months its review of Bluebird's treatments for beta thalassemia and a rare brain disorder, the latest delay in the company's lengthy road to market in the U.S.
World of DTC Marketing
JANUARY 17, 2022
Thyroid eye disease affects more women than men, although men are more likely to have severe illnesses. The exact prevalence of thyroid eye disease is not known, but is estimated to be 16 per 100,000 women in the general population, and 2.9 per 100,000 men in the general population. So why in the hell is Tepezza running TV ads? Do Millennials know how to market to older consumers?
BioPharma Reporter
JANUARY 20, 2022
Valneva announced yesterday that results from a lab study showed three doses of its inactivated COVID-19 vaccine candidate, VLA2001, neutralized the Omicron variant.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
JANUARY 18, 2022
Microsoft and CVS Health have announced a new strategic alliance focusing on personalised care and accelerating digital transformation for the benefit of CVS customers and its employees. David Rhew, MD, global chief medical officer and VP of healthcare at Microsoft, tells us, “Using Microsoft technology, CVS Health will develop a more agile, digital-first technology foundation.” Digital innovation and implementation have skyrocketed within healthcare due to the need to adapt quickly
Bio Pharma Dive
JANUARY 20, 2022
Frank Clyburn, a Merck veteran and head of the company's human health division, will leave next month to run IFF, following the exit of other top leaders at the drugmaker.
World of DTC Marketing
JANUARY 21, 2022
Omnichannel is the latest buzzword-making rounds within pharma, but omnichannel has no relevance if your message is too promotional or is irrelevant to your audience. The channel IS essential but not as important as your message. 68% of HCPs indicate webinars or webcasts as their most preferred channel to receive information. It is evident that HCPs are extremely time constraint and prefer to engage with pharma organizations on their terms regarding channel, content, and type of devices.
BioPharma Reporter
JANUARY 20, 2022
A new vaccine manufacturing plant has been opened in Cape Town by South Africa president Cyril Ramaphosa this week.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
JANUARY 17, 2022
After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position in the obesity space through a collaboration with EraCal Therapeutics. Under the joint research plan, the Danish giant will work with EraCal to identify novel drug targets relevant for food intake regulation and additional metabolic phenotypes. Although specific details of the collaboration are yet to be released, EraCal has confirmed that the duo will utilise its phenotypic drug discovery platform to id
Bio Pharma Dive
JANUARY 19, 2022
Study results show EQRx's drug, which it means to position as a lower-cost alternative to widely used cancer immunotherapies, extended the lives of lung cancer patients. But it's unclear whether that will be enough to sway the FDA.
XTalks
JANUARY 17, 2022
Abbott’s new cardiac mapping platform, EnSite X EP System, has received clearance from the US Food and Drug Administration (FDA) for the treatment of cardiac arrhythmias. The cardiac mapping system incorporates Abbott’s proprietary EnSite Omnipolar Technology (OT), which allows for 360° mapping to generate better and “true” electrograms (EGM) using the Advisor HD Grid Catheter.
BioPharma Reporter
JANUARY 19, 2022
Automated cell therapy manufacturing processes could reduce manual intervention and human errors, enabling more robust processes, improved product quality, and lower costs.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JANUARY 17, 2022
A World Health Organization (WHO) panel has given the green light to two new drugs to treat COVID-19. US-based Eli Lilly’s baricitinib (Olumiant), a Janus kinase inhibitor, and GlaxoSmithKline and Vir Biotechnology’s sotrovimab, a monoclonal antibody, were recommended in new WHO guidelines, published in the British Medical Journal. . Baricitinib, administered with corticosteroids, was strongly recommended as a treatment for patients with severe or critical illness.
Bio Pharma Dive
JANUARY 18, 2022
Ten months after Roche stopped giving the drug to patients in a Phase 3 trial, the pharma is planning a new study on the belief the medicine may help younger adult patients with less advanced disease.
Pharma Times
JANUARY 21, 2022
New figures from Health Education England (HEE) show that the pharmacist vacancy rate in community pharmacies across England has doubled to 8% between 2017 and 2021.
BioPharma Reporter
JANUARY 18, 2022
Regulatory bodies in the European Union have launched an initiative to develop the region as a focal point for clinical research and to better integrate clinical research in the European health system.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
pharmaphorum
JANUARY 17, 2022
GlaxoSmithKline (GSK) claims it has rejected three unsolicited, conditional and non-binding proposals from Unilever to acquire GSK Consumer Healthcare in a deal worth approximately $68.4 billion (£50 billion). The Consumer Healthcare business is a Joint Venture between GSK and Pfizer, with GSK holding a majority controlling interest of 68% and Pfizer 32%.
Bio Pharma Dive
JANUARY 18, 2022
AbbVie's Rinvoq and Pfizer's Cibinqo are both JAK-inhibiting drugs that are taken orally, a convenience which could help them compete against injectable treatments like Sanofi and Regeneron's Dupixent.
Pharma Times
JANUARY 20, 2022
The drug received conditional marketing authorisation in the UK from the MHRA in November
BioPharma Reporter
JANUARY 17, 2022
Andelyn Biosciences says the FDA's acceptance of its GMP plasmid DNA drug master file (DMF) enables the CDMO to vertically integrate its clientsâ manufacturing process, condensing timelines for developers to begin manufacturing to just three months.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
JANUARY 20, 2022
US pharma giant Gilead Sciences has accused a network of unauthorised suppliers and distributors of selling more than $250 million of counterfeit versions of its HIV medications. According to the company, the defendants reportedly sold 85,247 bottles of medicine with counterfeit Gilead labelling to pharmacies over a two-year period, using falsified supply chain documentation to conceal their origin.
Bio Pharma Dive
JANUARY 19, 2022
The acquisition will give the Belgian pharma access to an epilepsy drug that won U.S. approval in June 2020 but that Zogenix has struggled to sell.
Intouch Solutions
JANUARY 21, 2022
Recently, LinkedIn shared the results of a biweekly survey of 5,000 U.S. professionals, and most striking, say the folks at the career-networking site, is “how much the pandemic-influenced worksite choices of 2020 have persisted.” In short, the survey showed that about half of workers are back onsite; about one-third continue to work remotely full time; and nearly one-fifth work using a hybrid approach.
BioPharma Reporter
JANUARY 18, 2022
Orgenesis and The Johns Hopkins University will construct a cell and gene therapy processing facility for point of care treatment of patients at Johns Hopkins.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
363 
Let's personalize your content